The First Affiliated Hospital Of Soochow University

This study tests a new way to treat aplastic anemia, a serious condition where the bone marrow stops making enough blood cells. Researchers are combining a parent's half-matched stem cells with umbilical cord blood to see if this helps the body accept the transplant better and lo…

This study tests a new mix of three drugs—zeprumetostat, azacitidine, and mitoxantrone hydrochloride liposome—in adults whose peripheral T-cell lymphoma has come back or not responded to earlier treatments. About 26 people will receive up to 6 cycles of the combination, then up t…

This study compares four different drug combinations for adults newly diagnosed with acute myeloid leukemia (AML) who cannot tolerate or choose not to have intensive chemotherapy. The combinations include venetoclax and azacitidine (VA) alone or with either cladribine, chidamide,…

This study tests whether the drug gilteritinib works better than sorafenib at keeping leukemia from coming back in people with a specific genetic mutation (FLT3-ITD) after a stem cell transplant. About 594 participants will be randomly assigned to take one of the two drugs for up…

This study tests a combination of three drugs (venetoclax, cladribine, and low-dose cytarabine) in 36 people aged 15-70 with relapsed or treatment-resistant Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. The goal is to see how many patients achieve complete…

This study tests a new approach for people newly diagnosed with a fast-growing blood cancer called diffuse large B-cell lymphoma that has a specific genetic change (TP53 mutation). The treatment is matched to each person's genetic subtype to improve effectiveness. About 35 adults…

This study tests a three-drug combination (cladribine, low-dose cytarabine, and venetoclax) in 68 adults aged 16-70 with acute myeloid leukemia that has come back or not responded to prior treatment. The goal is to see if this combo can shrink or eliminate the cancer. Participant…

This study looks at whether menin inhibitors can help prevent leukemia from coming back after a stem cell transplant. About 20 people with certain genetic types of acute leukemia will take these drugs as part of their regular care. Researchers will track how long they stay cancer…

This study is testing whether combining two drugs, romiplostim and rituximab, can safely raise platelet counts in adults with immune thrombocytopenia (ITP) who did not get better with standard oral treatments. About 30 participants will receive both drugs for several weeks and be…

This study tests a three-drug combination (chidamide, venetoclax, and azacitidine) in adults with acute myeloid leukemia whose cancer did not respond to the first round of venetoclax and azacitidine. The goal is to see if adding chidamide can improve remission rates. About 32 par…

This study tests a new combination of drugs (cladribine, lisaftolax, and busulfan) given before a stem cell transplant in 30 older adults (50+) with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. The goal is to make the transplant safer and more ef…

This study tests a new approach for people with a slow-growing lymphoma called marginal zone lymphoma (MZL). Participants first get a short course of standard chemo, then a targeted drug (Orelabrutinib) to keep the cancer under control. The goal is to see if this approach improve…

This study tests a new treatment plan for people newly diagnosed with a type of blood cancer called B-cell acute lymphoblastic leukemia. The plan combines a reduced dose of chemotherapy with a full course of immunotherapy (blinatumomab) and, for some patients, CAR-T cell therapy …

This study tests a two-step immunotherapy approach for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older, too frail for standard chemo, or whose cancer has returned. Participants will receive two targeted drugs in sequence: blinatumomab and inotuzumab ozogamic…

This study tests a combination of three drugs (venetoclax, azacytidine, and chidamide) for people newly diagnosed with a specific type of leukemia called acute monocytic leukemia who are not healthy enough for standard intensive chemotherapy. The goal is to see if this drug combo…

This study tests a personalized cell therapy (CAR T-cells) for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The therapy uses the patient's own immune cells, modified to target and kill cancer cells. The goal is to…

This study tests whether a once-weekly injection (romiplostim) can help platelets recover faster and more safely after a donor stem cell transplant in people with myelodysplastic syndrome (MDS) or severe aplastic anemia. About 66 adults will be randomly assigned to receive either…

This early-phase study tests a new treatment called CT0596 CAR-T cells for people with multiple myeloma or plasma cell leukemia that has come back or not responded to standard therapies. The main goals are to check safety and find the right dose. About 24 adults will take part, a…

This study tests a combination of three treatments (PD-1 inhibitor, azacitidine, and low-dose donor lymphocyte infusion) for people whose acute myeloid leukemia has come back after a stem cell transplant. The goal is to see if this approach can control the disease and improve sur…

This study tests whether combining two drugs, venetoclax and azacitidine, can help people newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). About 28 participants aged 15 and older will receive the treatment to see how many achieve remission. The goal is to find a …

This study tests whether giving patients their own healthy gut bacteria (via a fecal transplant) can prevent acute graft-versus-host disease, a serious complication where donor immune cells attack the patient's body after a stem cell transplant. About 100 people receiving a half-…

This early study tests a new approach for adults with B-cell acute lymphoblastic leukemia who cannot or choose not to have a donor stem cell transplant. The treatment combines the drug blinatumomab with the patient's own stem cells in a 'sandwich' strategy to reduce relapse risk.…

This study tests whether a maintenance drug (hypomethylating agent) can help people with a favorable type of acute myeloid leukemia (AML) stay in remission longer. About 77 adults who have already achieved remission after initial treatment will receive the drug. The goal is to se…

This early-phase study tests a new oral drug, BY002, in about 18 adults with acute leukemia that has come back or not responded to standard treatments. The drug targets specific genetic changes (KMT2A rearrangements or NPM1 mutations) to control the disease. The main goals are to…

This study tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) in adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CEBPA-mutated) who cannot tolerate strong chemotherapy. The goal is to see if this tre…

This study is testing a new treatment called U96, a type of CAR-T therapy that works inside the body, for people with relapsed or refractory B-cell leukemia or lymphoma. About 30 adults will receive the therapy and be monitored for safety and how well the cancer responds. The goa…

This study tests whether combining zanubrutinib (a pill) with rituximab (an infusion) can control a dangerous immune overreaction called HLH that happens in people with B-cell lymphoma. About 40 adults aged 14-80 will receive the drugs for 4 weeks, along with other medications li…

This study tests a combination of three drugs (pirtobrutinib, lisaftoclax, and rituximab) in 29 adults with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or eliminate tumors. Pa…

This study tests if a new chemotherapy combination (TmBU) works better than the standard one (mBUCY) before a stem cell transplant for people with high-risk or hard-to-treat acute leukemia. About 48 adults aged 65 or younger will be randomly assigned to one of the two regimens. T…

This study tests whether a combination of three drugs (an anti-PD-1 antibody, lenalidomide, and azacitidine) can shrink tumors or stop them from growing in people with peripheral T-cell lymphoma that has come back or not responded to prior treatments. About 31 participants will r…

This early-stage trial tests a new treatment called U69, which uses specially engineered immune cells (CAR-T cells) to find and attack cancer cells in patients with T-cell leukemia or lymphoma that has come back or not responded to standard treatments. The study aims to check the…

This study tests a combination of five drugs (venetoclax, azacitidine, chidamide, vindesine, and dexamethasone) in adults newly diagnosed with a rare, aggressive leukemia called ETP-ALL. The goal is to see if this mix can help more patients achieve remission. About 27 people will…

This study tests a new drug combination (venetoclax plus other medicines) without traditional strong chemotherapy for adults newly diagnosed with a rare genetic subtype of acute myeloid leukemia. The goal is to see if this gentler approach can achieve complete remission and reduc…

This study is testing an artificial intelligence (AI) model that helps doctors detect early gastric cancer during endoscopic exams. The AI combines different types of images and patient data to improve accuracy and explain its reasoning. About 100 adults with suspicious stomach l…

This study looks at whether a blood test can accurately diagnose systemic mastocytosis, a rare disease where too many mast cells build up in the body. Currently, diagnosis requires a painful bone marrow biopsy. Researchers will test blood samples from 50 adults using a highly sen…

This study is testing new types of MRI scans to see if they can more accurately find and grade prostate cancer without using a contrast dye. About 300 men with suspected prostate cancer will get both standard and new MRI scans. The results will be checked against biopsy or surger…

This study tests whether a single infusion of amimestrocel, a cell therapy made from human umbilical cord cells, can prevent severe mouth and gut sores in patients receiving a stem cell transplant. About 22 adults will receive the infusion 1-2 days before their transplant. Resear…

This study tests whether taking letermovir for a longer time (up to 28 weeks) can prevent cytomegalovirus (CMV) infection in 330 high-risk Chinese adults who have received a stem cell transplant. CMV is a common and serious complication in these patients because their immune syst…

This early-stage study tests a new drug called IBI3002 in adults with asthma. The main goal is to check if multiple doses are safe and tolerable. About 12 to 27 participants will receive either the drug or a placebo by injection. The study lasts about 24 weeks total, including sc…

This study tests whether low-frequency magnetic stimulation to a specific brain area can reduce chronic visceral pain in people with irritable bowel syndrome with diarrhea (IBS-D). 42 adults will receive either real or sham stimulation over two weeks, with both participants and a…

This study looks at whether the temperature of the numbing medicine used in epidurals affects the chance of a mother developing a fever during labor. Researchers will give 424 women either room-temperature or body-temperature anesthetic and track fever rates, pain relief, and hea…

This study looks at the nutritional health of 200 people who have had a stem cell transplant. Researchers will measure body composition, food intake, and blood protein levels over six months. The goal is to understand how nutrition affects recovery and long-term survival.

This study looks at how the body breaks down certain carbohydrates (FODMAPs) in the gut and whether that affects graft-versus-host disease (GVHD) after a bone marrow transplant. Researchers will follow 100 transplant patients to track when and how severe GVHD occurs. The goal is …